Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Leukemia

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2024

Lymphoma

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

Leukemia

Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Ru Y, Chen J, Ferhat AT, Labussière-Wallet H, Gedde-Dahl T, Kröger N, Socié G, Yakoub-Agha I, Eder M, Mielke S, Wu D, Mohty M, Ciceri F, Gorin NC

doi: 10.1002/ajh.70069

Leukemia

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Leukemia

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M

doi: 10.1038/s41375-024-02501-6

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement